• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

是否治疗:有症状的玻璃体漂浮物的治疗选择。

To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters.

机构信息

Save Sight Institute, The University of Sydney, Sydney, Australia.

Sydney Institute of Vision Science, Sydney, Australia.

出版信息

Asia Pac J Ophthalmol (Phila). 2020 Mar-Apr;9(2):96-103. doi: 10.1097/APO.0000000000000276.

DOI:10.1097/APO.0000000000000276
PMID:32097127
Abstract

Vitreous floaters are a common cause for presentation to ophthalmologists, and may significantly affect visual function. In the absence of some more serious underlying pathology such as uveitis, many patients may not experience significant persistent visual impairment from floaters. For some patients, the symptomatic effects of floaters may persist. For these patients, treatment options are available, of which the most commonly reported is vitrectomy. Other treatment modalities have also become more common, notably YAG vitreolysis. Selection of appropriate patients for surgery is often difficult, in part due to the relative lack of objective outcomes with which to measure both visual impairment and improvement post-procedure. Although well-tolerated, vitrectomy does carry with it risks, including iatrogenic retinal breaks, retinal detachment, and in phakic patients, subsequent cataract formation. Techniques such as small gauge vitrectomy, intraoperative examination and treatment of breaks or other worrying lesions, and careful consideration of the need for posterior vitreous detachment induction may help limit the incidence of these adverse events. For other treatment options such as YAG vitreolysis, research and clinical experience remain more limited, and as such the long-term efficacy and risks of these therapies are still unclear. Here, we review the evidence surrounding the role of vitrectomy and YAG vitreolysis in the treatment of vitreous floaters and potential means to minimize therapeutic complications.

摘要

玻璃体浮游物是眼科就诊的常见原因,可能会显著影响视觉功能。在没有一些更严重的潜在疾病(如葡萄膜炎)的情况下,许多患者可能不会因浮游物而出现明显的持续性视力损害。对于一些患者,浮游物的症状影响可能会持续存在。对于这些患者,有治疗选择,其中最常报告的是玻璃体切除术。其他治疗方式也变得更加常见,尤其是 YAG 玻璃体切割术。选择合适的手术患者通常很困难,部分原因是缺乏客观的结果来衡量视觉损伤和术后改善。尽管玻璃体切除术耐受性良好,但它确实存在风险,包括医源性视网膜裂孔、视网膜脱离,以及在有晶状体患者中,随后发生白内障。一些技术,如小口径玻璃体切除术、术中检查和治疗裂孔或其他令人担忧的病变,以及仔细考虑是否需要后玻璃体脱离诱导,可能有助于降低这些不良事件的发生率。对于 YAG 玻璃体切割术等其他治疗选择,研究和临床经验仍然更为有限,因此这些治疗的长期疗效和风险仍不清楚。在这里,我们回顾了玻璃体切除术和 YAG 玻璃体切割术在治疗玻璃体浮游物中的作用的证据,并探讨了最小化治疗并发症的潜在方法。

相似文献

1
To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters.是否治疗:有症状的玻璃体漂浮物的治疗选择。
Asia Pac J Ophthalmol (Phila). 2020 Mar-Apr;9(2):96-103. doi: 10.1097/APO.0000000000000276.
2
Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters.钕钇铝石榴石激光玻璃体溶解术与玻璃体切割术治疗玻璃体混浊的对比研究
Cochrane Database Syst Rev. 2017 Jun 1;6(6):CD011676. doi: 10.1002/14651858.CD011676.pub2.
3
YAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters: A Randomized Clinical Trial.YAG激光玻璃体溶解术与假性YAG玻璃体溶解术治疗有症状玻璃体混浊的随机临床试验
JAMA Ophthalmol. 2017 Sep 1;135(9):918-923. doi: 10.1001/jamaophthalmol.2017.2388.
4
Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters.钕钇铝石榴石玻璃体溶解术和平坦部玻璃体切除术:玻璃体混浊的手术治疗
Eye (Lond). 2002 Jan;16(1):21-6. doi: 10.1038/sj.eye.6700026.
5
LASER VITREOLYSIS IN PATIENTS WITH SYMPTOMATIC VITREOUS FLOATERS.有症状玻璃体混浊患者的激光玻璃体溶解术
Cesk Slov Oftalmol. 2022 Fall;78(6):288-295. doi: 10.31348/2022/28.
6
Modern vitreolysis-YAG laser treatment now a real solution for the treatment of symptomatic floaters.现代玻璃体切除术 - YAG 激光治疗现在是治疗有症状的飞蚊症的真正解决方案。
Surv Ophthalmol. 2020 Sep-Oct;65(5):581-588. doi: 10.1016/j.survophthal.2020.02.006. Epub 2020 Mar 3.
7
Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption.激光玻璃体切除术治疗有症状的飞蚊症尚不成熟,尚未广泛采用。
Surv Ophthalmol. 2020 Sep-Oct;65(5):589-591. doi: 10.1016/j.survophthal.2020.02.007. Epub 2020 Mar 3.
8
Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview.YAG 激光玻璃体液化治疗飞蚊症的安全性和疗效:综述。
Adv Ther. 2020 Apr;37(4):1319-1327. doi: 10.1007/s12325-020-01261-w. Epub 2020 Feb 21.
9
Novel OCT Application and Optimized YAG Laser Enable Visualization and Treatment of Mid- to Posterior Vitreous Floaters.新型光学相干断层扫描(OCT)应用与优化的钇铝石榴石(YAG)激光实现对中后段玻璃体混浊的可视化及治疗
Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 1;49(10):806-811. doi: 10.3928/23258160-20181002-10.
10
Management of vitreous floaters: a review.玻璃体混浊的处理:综述。
Curr Opin Ophthalmol. 2024 Sep 1;35(5):365-368. doi: 10.1097/ICU.0000000000001075. Epub 2024 Jul 11.

引用本文的文献

1
Management of Visually Significant Vitreous Opacities.显著玻璃体混浊的处理。
Mo Med. 2024 Sep-Oct;121(5):391-394.
2
Long-term efficacy and safety of YAG laser vitreolysis for vision degrading myodesopsia.YAG激光玻璃体溶解术治疗视力下降性飞蚊症的长期疗效和安全性。
Int J Ophthalmol. 2023 Nov 18;16(11):1800-1805. doi: 10.18240/ijo.2023.11.10. eCollection 2023.
3
Vision degrading myodesopsia assessed with optos ultra-widefield scanning laser ophthalmoscope.采用光学生物测量仪超广角扫描激光检眼镜评估进行性视力丧失性眼球震颤。
BMC Ophthalmol. 2023 Oct 20;23(1):425. doi: 10.1186/s12886-023-03166-y.
4
Spontaneous remission of vision degrading myodesopsia of posterior vitreous detachment type.后玻璃体脱离型眼球运动障碍的自发缓解导致视力下降。
Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1571-1577. doi: 10.1007/s00417-022-05948-4. Epub 2022 Dec 24.
5
A New Pharmacological Vitreolysis through the Supplement of Mixed Fruit Enzymes for Patients with Ocular Floaters or Vitreous Hemorrhage-Induced Floaters.通过补充混合水果酶对飞蚊症或玻璃体出血引起的飞蚊症患者进行新型药理玻璃体溶解术。
J Clin Med. 2022 Nov 13;11(22):6710. doi: 10.3390/jcm11226710.
6
The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD.YAG激光玻璃体溶解术治疗完全性或非完全性玻璃体后脱离所致症状性玻璃体混浊的疗效与安全性
Ophthalmol Ther. 2022 Feb;11(1):201-214. doi: 10.1007/s40123-021-00422-6. Epub 2021 Nov 15.